Hannah Bleasdale-Wallis
Research Subjects
Hannah Bleasdale-Wallis has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Afisi Segun Ismaila
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada
1 shared publication - Alexandrosz Czira
Value Evidence and Outcomes, R&D Global Medical, GSK, Brentford, UK
1 shared publication - Charley Cooper1 shared publication
- Doreen A. Kahangire1 shared publication
- Iqra Syed
AstraZeneca Canada, Mississauga, ON, Canada
1 shared publication Joanna de Courcy
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Multidisciplinary team perceptions towards the treatment of limited-stage small-cell lung cancer; a United States physician survey
Background Treatment paradigms for limited-stage small cell lung cancer (LS-SCLC) have remained unchanged for decades, focusing on multi-disciplinary team (MDT) coordination, with treatments including concurrent chemoradiotherapy (cCRT) for the majority of patients, with optional prophylactic cranial irradiation (PCI). With the introduction of immunotherapy (IO) for LS-SCLC, there is a need to assess the real-world application of current treatment guidance. Methods Cross-sectional survey of medical oncologists (MedO) and radiation oncologists (RadO) in the US, conducted August-October 2024. Oncologists reported on their use of cCRT and PCI, and their views on upcoming IO therapies. Results Of the 177 oncologists (MedO: n=87; RadO: n=90), 94.9% reported attending an MDT, with 53.4% reporting weekly MDT meetings. Oncologists stated that among their LS-SCLC patients receiving CRT,a median 90.0% (IQR: 55.0%, 95.0%) of them received cCRT, most commonly with cisplatin/etoposide (55.4%). Common barriers to cCRT use were patient comorbidities (48.6%) and treatment toxicity (46.9%). Facilitators included presence of a nurse navigator (59.8%). Half of patients typically received PCI, with concern about patient cognitive decline (54.9%) and patient refusal (53.7%) being the most common reasons for PCI deferral. The majority of physicians were familiar with upcoming IO therapies, and likely to prescribe them. Side effects (37.9%) and radiotherapy-related pneumonitis (32.8%) were the most commonly reported reasons for not prescribing IO. Conclusion Although cCRT is commonly used, barriers remain, highlighting need for less burdensome treatments. A high reported likelihood of prescribing emerging IO therapies suggests a shift towards improved patient and clinical outcomes in routine clinical practice.
- 6 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMultidisciplinary team perceptions towards the treatment of limited-stage small-cell lung cancer; a United States physician survey
Background Treatment paradigms for limited-stage small cell lung cancer (LS-SCLC) have remained unchanged for decades, focusing on multi-disciplinary team (MDT) coordination, with treatments including concurrent chemoradiotherapy (cCRT) for the majority of patients, with optional prophylactic cranial irradiation (PCI). With the introduction of immunotherapy (IO) for LS-SCLC, there is a need to assess the real-world application of current treatment guidance. Methods Cross-sectional survey of medical oncologists (MedO) and radiation oncologists (RadO) in the US, conducted August-October 2024. Oncologists reported on their use of cCRT and PCI, and their views on upcoming IO therapies. Results Of the 177 oncologists (MedO: n=87; RadO: n=90), 94.9% reported attending an MDT, with 53.4% reporting weekly MDT meetings. Oncologists stated that among their LS-SCLC patients receiving CRT,a median 90.0% (IQR: 55.0%, 95.0%) of them received cCRT, most commonly with cisplatin/etoposide (55.4%). Common barriers to cCRT use were patient comorbidities (48.6%) and treatment toxicity (46.9%). Facilitators included presence of a nurse navigator (59.8%). Half of patients typically received PCI, with concern about patient cognitive decline (54.9%) and patient refusal (53.7%) being the most common reasons for PCI deferral. The majority of physicians were familiar with upcoming IO therapies, and likely to prescribe them. Side effects (37.9%) and radiotherapy-related pneumonitis (32.8%) were the most commonly reported reasons for not prescribing IO. Conclusion Although cCRT is commonly used, barriers remain, highlighting need for less burdensome treatments. A high reported likelihood of prescribing emerging IO therapies suggests a shift towards improved patient and clinical outcomes in routine clinical practice.
- Open Access
- 1 December 2023
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 18, 2933-2953
Benefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study
Purpose: There is currently limited evidence for the optimal timing of triple therapy initiation in Japan, which is crucial for optimizing strategies for the effective treatment of chronic obstructive pulmonary disease (COPD). This study assessed the impact of prompt vs delayed initiation of triple therapy following a COPD exacerbation on clinical and economic outcomes in patients in Japan. Patients and Methods: Retrospective cohort study of patients in the Medical Data Vision Co., Ltd. database initiating triple therapy as single-inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol or budesonide/glycopyrronium/formoterol) or multiple-inhaler triple therapy within 180 days of a moderate-to-severe exacerbation (index). For the main analysis, patients were categorized as prompt or delayed initiators, initiating triple therapy within 0– 30 days or 31– 180 days of index, respectively. Inverse probability of treatment weighting based on propensity scores was used to adjust for measured confounders between prompt and delayed cohorts. Results: For the main analysis, 610 (60.3%) and 402 (39.7%) patients were prompt and delayed initiators, respectively. The rate of subsequent moderate-to-severe exacerbations following index exacerbation was numerically lower in prompt vs delayed initiators (weighted rate ratio 0.95, 95% confidence interval [CI]: 0.74– 1.21; P = 0.6603). Time-to-first subsequent moderate-to-severe exacerbation increased significantly in prompt vs delayed initiators (weighted hazard ratio 0.77, 95% CI: 0.64– 0.93; P = 0.0053). In patients indexed on a severe exacerbation, delayed initiation resulted in significantly higher 90-day all-cause readmissions vs prompt initiation (42.1% vs 30.6%; P = 0.0329 [weighted estimates]). Weighted healthcare resource utilization rates were numerically lower in prompt vs delayed initiators, and weighted direct costs (all cause and COPD-related) were significantly lower in prompt initiators. Conclusion: This real-world study demonstrated that earlier initiation of triple therapy resulted in several benefits in clinical outcomes for COPD and may also reduce the economic burden of COPD management in Japan. Plain Language Summary: Patients with chronic obstructive pulmonary disease (COPD) can experience flare-ups in their symptoms, known as exacerbations. If exacerbations continue despite patients taking either one or a combination of two respiratory medications, guidelines suggest that they should take a combination of three treatments, known as triple therapy. In Japan, the best timing for patients to start triple therapy following an exacerbation is currently unknown, therefore this study compared the impact on clinical and economic outcomes of patients starting triple therapy 0– 30 days (prompt initiators) or 31– 180 days (delayed initiators) after their first exacerbation. When looking at clinical outcomes for COPD, we found that prompt initiators had a significantly longer time period from starting triple therapy to experiencing their next moderate-to-severe exacerbation, and those who had an initial severe exacerbation had significantly fewer hospital readmissions during the 90 days that followed their initial exacerbation than delayed initiators. When looking at economic outcomes for COPD, we found that medical costs were significantly lower in prompt versus delayed initiators. Findings of this study suggest that starting triple therapy earlier following an exacerbation may lead to improved clinical outcomes for patients with COPD in Japan and can reduce the cost of managing this disease.
- 1 December 2023
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 18, 2933-2953
Open AccessBenefit of Prompt Vs Delayed Initiation of Triple Therapy Following an Exacerbation in Patients with COPD in Japan: A Retrospective Cohort Study
Purpose: There is currently limited evidence for the optimal timing of triple therapy initiation in Japan, which is crucial for optimizing strategies for the effective treatment of chronic obstructive pulmonary disease (COPD). This study assessed the impact of prompt vs delayed initiation of triple therapy following a COPD exacerbation on clinical and economic outcomes in patients in Japan. Patients and Methods: Retrospective cohort study of patients in the Medical Data Vision Co., Ltd. database initiating triple therapy as single-inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol or budesonide/glycopyrronium/formoterol) or multiple-inhaler triple therapy within 180 days of a moderate-to-severe exacerbation (index). For the main analysis, patients were categorized as prompt or delayed initiators, initiating triple therapy within 0– 30 days or 31– 180 days of index, respectively. Inverse probability of treatment weighting based on propensity scores was used to adjust for measured confounders between prompt and delayed cohorts. Results: For the main analysis, 610 (60.3%) and 402 (39.7%) patients were prompt and delayed initiators, respectively. The rate of subsequent moderate-to-severe exacerbations following index exacerbation was numerically lower in prompt vs delayed initiators (weighted rate ratio 0.95, 95% confidence interval [CI]: 0.74– 1.21; P = 0.6603). Time-to-first subsequent moderate-to-severe exacerbation increased significantly in prompt vs delayed initiators (weighted hazard ratio 0.77, 95% CI: 0.64– 0.93; P = 0.0053). In patients indexed on a severe exacerbation, delayed initiation resulted in significantly higher 90-day all-cause readmissions vs prompt initiation (42.1% vs 30.6%; P = 0.0329 [weighted estimates]). Weighted healthcare resource utilization rates were numerically lower in prompt vs delayed initiators, and weighted direct costs (all cause and COPD-related) were significantly lower in prompt initiators. Conclusion: This real-world study demonstrated that earlier initiation of triple therapy resulted in several benefits in clinical outcomes for COPD and may also reduce the economic burden of COPD management in Japan. Plain Language Summary: Patients with chronic obstructive pulmonary disease (COPD) can experience flare-ups in their symptoms, known as exacerbations. If exacerbations continue despite patients taking either one or a combination of two respiratory medications, guidelines suggest that they should take a combination of three treatments, known as triple therapy. In Japan, the best timing for patients to start triple therapy following an exacerbation is currently unknown, therefore this study compared the impact on clinical and economic outcomes of patients starting triple therapy 0– 30 days (prompt initiators) or 31– 180 days (delayed initiators) after their first exacerbation. When looking at clinical outcomes for COPD, we found that prompt initiators had a significantly longer time period from starting triple therapy to experiencing their next moderate-to-severe exacerbation, and those who had an initial severe exacerbation had significantly fewer hospital readmissions during the 90 days that followed their initial exacerbation than delayed initiators. When looking at economic outcomes for COPD, we found that medical costs were significantly lower in prompt versus delayed initiators. Findings of this study suggest that starting triple therapy earlier following an exacerbation may lead to improved clinical outcomes for patients with COPD in Japan and can reduce the cost of managing this disease.